Is there any research supporting taking Mirabegron (Myrbetriq) twice daily instead of once daily for dose escalation?

Mirabegron Twice Daily Dosing: Not Supported by Evidence

There is no research evidence supporting twice-daily dosing of mirabegron (Myrbetriq) for overactive bladder, and this approach contradicts FDA-approved labeling which specifies once-daily administration only. 1

FDA-Approved Dosing

The FDA label for Myrbetriq explicitly establishes once-daily dosing as the standard regimen 1:

• Starting dose: 25 mg once daily
• Maintenance dose: 50 mg once daily (can be increased from 25 mg based on efficacy and tolerability)
• Maximum studied dose: 100 mg once daily (though not commonly used in practice)

All pivotal Phase III trials evaluated mirabegron administered once daily only 2. The European Association of Urology guidelines reference multiple studies using 25 mg, 50 mg, and 100 mg doses, but all were administered once daily 2.

Evidence for Dose Escalation (Once Daily)

If inadequate response occurs at 25 mg once daily, the evidence-based approach is to increase to 50 mg once daily, not to split the dose twice daily 3:

• A randomized trial in 242 Asian patients demonstrated that escalating from 25 mg to 50 mg once daily significantly improved daily urgency episodes (60.9% vs 34.5%, p=0.034) and urgency urinary incontinence episodes (87.5% vs 37.5%, p=0.021) in patients with residual symptoms 3
• The 50 mg once-daily dose showed superior efficacy to 25 mg in multiple Phase III trials without increased adverse events 4
• Meta-analysis of nine Phase II/III trials confirmed that 50 mg once daily, long-term, maximizes benefit in middle-aged and older adults 5

Why Twice Daily Dosing Is Not Appropriate

The pharmacokinetic profile of mirabegron does not support twice-daily dosing 1:

• Mirabegron is formulated as an extended-release tablet designed for once-daily administration
• The drug has a long half-life that maintains therapeutic levels over 24 hours with once-daily dosing
• All safety and efficacy data come from once-daily regimens; twice-daily dosing has never been studied

Splitting the dose would likely increase adverse events without improving efficacy 1:

• Common adverse events (hypertension, tachycardia, urinary retention) are dose-related 1
• The incidence of hypertension was 7.5-11.3% with standard once-daily dosing 1
• More frequent dosing could increase cardiovascular risks, particularly in elderly patients

Recommended Approach for Inadequate Response

If a patient fails to respond adequately to mirabegron 50 mg once daily, the evidence supports these alternatives 6:

1. Add an antimuscarinic agent (combination therapy): The SYNERGY and BESIDE trials demonstrated that combining solifenacin 5 mg with mirabegron 50 mg once daily provides additive benefits without significantly increased adverse events 6, 7

2. Switch to alternative monotherapy: Consider different antimuscarinic agents or other β3-agonists 2

3. Advance to third-line therapies: Intradetrusor onabotulinumtoxin, peripheral tibial nerve stimulation, or sacral neuromodulation 6

Common Pitfall to Avoid

Do not confuse mirabegron dosing with PPI dosing strategies: While twice-daily dosing is commonly used for proton pump inhibitors when once-daily fails 8, this approach does not apply to mirabegron. The urologist may be inappropriately extrapolating dosing strategies from other medication classes.

The correct dose escalation for mirabegron is 25 mg → 50 mg once daily, not splitting into twice-daily administration 1, 3, 5.